Oncotarget

Research Papers:

GBM heterogeneity as a function of variable epidermal growth factor receptor variant III activity

Olle R. Lindberg, Andrew McKinney, Jane R. Engler, Gayane Koshkakaryan, Henry Gong, Aaron E. Robinson, Andrew J. Ewald, Emmanuelle Huillard, C. David James, Annette M. Molinaro, Joseph T. Shieh and Joanna J. Phillips _

PDF  |  HTML  |  Supplementary Files  |  How to cite

Oncotarget. 2016; 7:79101-79116. https://doi.org/10.18632/oncotarget.12600

Metrics: PDF 1866 views  |   HTML 3044 views  |   ?  


Abstract

Olle R. Lindberg1, Andrew McKinney1, Jane R. Engler1, Gayane Koshkakaryan2, Henry Gong1, Aaron E. Robinson1, Andrew J. Ewald3, Emmanuelle Huillard4, C. David James5, Annette M. Molinaro1,6,7, Joseph T. Shieh8, Joanna J. Phillips1,6,9

1Department of Neurological Surgery, Brain Tumor Center, University of California, San Francisco, CA, USA

2Touro University California, College of Osteopathic Medicine. Vallejo, CA, USA

3Departments of Cell Biology, Oncology, and Biomedical Engineering, School of Medicine, Johns Hopkins University, Baltimore, MD, USA

4Université Pierre et Marie Curie (UPMC) UMR-S975, Inserm U1127, CNRS UMR7225, Institut du Cerveau et de la Moelle Epiniere, Paris, France

5Department of Neurological Surgery, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA

6Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, CA, USA

7Epidemiology and Biostatistics, University of California, San Francisco, CA, USA

8Institute for Human Genetics, Department of Pediatrics, University of California, San Francisco, CA, USA

9Department of Pathology, Division of Neuropathology, University of California, San Francisco, CA, USA

Correspondence to:

Joanna J. Phillips, email: [email protected]

Keywords: RTK activity, extracellular matrix, tumor heterogeneity, vessel co-option, invasion

Received: August 06, 2016    Accepted: September 29, 2016    Published: October 12, 2016

ABSTRACT

Abnormal activation of the epidermal growth factor receptor (EGFR) due to a deletion of exons 2-7 of EGFR (EGFRvIII) is a common alteration in glioblastoma (GBM). While this alteration can drive gliomagenesis, tumors harboring EGFRvIII are heterogeneous. To investigate the role for EGFRvIII activation in tumor phenotype we used a neural progenitor cell-based murine model of GBM driven by EGFR signaling and generated tumor progenitor cells with high and low EGFRvIII activation, pEGFRHi and pEGFRLo. In vivo, ex vivo, and in vitro studies suggested a direct association between EGFRvIII activity and increased tumor cell proliferation, decreased tumor cell adhesion to the extracellular matrix, and altered progenitor cell phenotype. Time-lapse confocal imaging of tumor cells in brain slice cultures demonstrated blood vessel co-option by tumor cells and highlighted differences in invasive pattern. Inhibition of EGFR signaling in pEGFRHi promoted cell differentiation and increased cell-matrix adhesion. Conversely, increased EGFRvIII activation in pEGFRLo reduced cell-matrix adhesion. Our study using a murine model for GBM driven by a single genetic driver, suggests differences in EGFR activation contribute to tumor heterogeneity and aggressiveness.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 12600